Axxcess Wealth Management LLC Has $577,000 Stock Position in Boston Scientific Co. (NYSE:BSX)

Axxcess Wealth Management LLC increased its stake in Boston Scientific Co. (NYSE:BSX) by 161.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 9,979 shares of the medical equipment provider’s stock after purchasing an additional 6,163 shares during the period. Axxcess Wealth Management LLC’s holdings in Boston Scientific were worth $577,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. FMR LLC lifted its position in shares of Boston Scientific by 6.8% in the third quarter. FMR LLC now owns 125,920,357 shares of the medical equipment provider’s stock worth $6,648,595,000 after purchasing an additional 8,045,263 shares in the last quarter. Vanguard Group Inc. lifted its position in Boston Scientific by 1.2% during the 3rd quarter. Vanguard Group Inc. now owns 123,768,348 shares of the medical equipment provider’s stock worth $6,534,969,000 after buying an additional 1,525,432 shares in the last quarter. Wellington Management Group LLP boosted its stake in shares of Boston Scientific by 5.9% during the 3rd quarter. Wellington Management Group LLP now owns 42,076,529 shares of the medical equipment provider’s stock worth $2,221,641,000 after buying an additional 2,336,348 shares during the last quarter. Morgan Stanley grew its holdings in shares of Boston Scientific by 2.3% in the 3rd quarter. Morgan Stanley now owns 21,200,339 shares of the medical equipment provider’s stock valued at $1,119,378,000 after acquiring an additional 481,891 shares in the last quarter. Finally, Invesco Ltd. increased its position in shares of Boston Scientific by 1.4% in the third quarter. Invesco Ltd. now owns 14,862,018 shares of the medical equipment provider’s stock valued at $784,715,000 after acquiring an additional 211,732 shares during the last quarter. Institutional investors own 89.07% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently commented on the company. Deutsche Bank Aktiengesellschaft increased their price target on Boston Scientific from $63.00 to $73.00 and gave the company a “hold” rating in a research report on Thursday, April 25th. StockNews.com cut shares of Boston Scientific from a “buy” rating to a “hold” rating in a research note on Saturday, March 16th. Needham & Company LLC upped their price target on shares of Boston Scientific from $71.00 to $82.00 and gave the stock a “buy” rating in a research report on Wednesday, April 24th. Citigroup lifted their price objective on shares of Boston Scientific from $79.00 to $85.00 and gave the company a “buy” rating in a research report on Thursday, April 25th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Boston Scientific from $72.00 to $82.00 and gave the stock an “overweight” rating in a research note on Thursday, April 25th. Three research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $75.09.

Insider Activity

In other news, Director Edward J. Ludwig sold 9,818 shares of the company’s stock in a transaction that occurred on Friday, April 26th. The stock was sold at an average price of $73.29, for a total value of $719,561.22. Following the transaction, the director now owns 41,374 shares of the company’s stock, valued at $3,032,300.46. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, Director Edward J. Ludwig sold 7,000 shares of the firm’s stock in a transaction on Tuesday, February 13th. The stock was sold at an average price of $65.03, for a total transaction of $455,210.00. Following the sale, the director now owns 41,374 shares of the company’s stock, valued at approximately $2,690,551.22. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Edward J. Ludwig sold 9,818 shares of the firm’s stock in a transaction on Friday, April 26th. The shares were sold at an average price of $73.29, for a total value of $719,561.22. Following the sale, the director now directly owns 41,374 shares in the company, valued at approximately $3,032,300.46. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 78,384 shares of company stock valued at $5,395,560. 0.50% of the stock is owned by insiders.

Boston Scientific Price Performance

Boston Scientific stock opened at $73.43 on Wednesday. Boston Scientific Co. has a 12 month low of $48.35 and a 12 month high of $74.39. The stock’s 50 day moving average is $68.68 and its 200-day moving average is $61.74. The company has a current ratio of 1.66, a quick ratio of 1.14 and a debt-to-equity ratio of 0.47. The company has a market capitalization of $107.73 billion, a price-to-earnings ratio of 61.71, a PEG ratio of 2.51 and a beta of 0.77.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.